Gauhati Medical College selected for COVAXIN 2nd phase clinical testing

The Gauhati Medical College and Hospital (GMCH) has been selected for the second phase clinical testing of India's indigenously developed coronavirus vaccine, COVAXIN, Assam Health Minister Himanta Biswa Sarma said on Tuesday.

He said the GMCH would provide all-out support for the second phase clinical testing of COVAXIN, which has already shown successful results in phase-one clinical trials.

According to the Minister, till Tuesday night, Assam has tested more than 18.22 lakh samples with 79,667 people testing positive for Covid-19. Of the total cases, 56,734 people have recovered from the disease with the recovery rate being 71.2 per cent and mortality rate 0.25 per cent.

Sarma said 197 people have died due to Covid-19 in the state so far. In terms of recovery rate, he said, five states -- Delhi, Tamil Nadu, Gujarat, West Bengal and Tripura -- were better than Assam.

--IANS

sc/khz


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel